Gilead Sciences, Inc EV/EBITDA
Data as of September 29, 2026
EV/EBITDA
N/A
Enterprise Value
$211.08B
EBITDA (TTM)
$-1.92B
Sector
Biotechnology
How It's Calculated
N/A = $211.08B ÷ $-1.92B
What This Means
EV/EBITDA is not meaningful when EBITDA is missing, negative, or near zero.
About Gilead Sciences, Inc
Gilead Sciences, Inc (GILD) operates in the Biotechnology sector, specifically in Biotechnology. With a market capitalization of about $188.01B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $152.21, within a 52-week range of $108.46 to $157.29 (-3.2% from the high, +40.3% from the low). Beta of 0.40 indicates relatively lower volatility versus the market.
Trailing profit margin is about -1064.0%, signaling negative or breakeven profitability, which can affect valuation multiples.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Gilead Sciences, Inc, the ratio should be read with growth, capex needs, and cycle position in Biotechnology. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the GILD metrics hub for related valuation pages.
Key Takeaways
- GILD is grouped in the Biotechnology sector for peer comparisons.
- Recent beta of 0.40 suggests lower-than-market price sensitivity.
- Trailing profit margin of -1064.0% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for GILD.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other GILD Metrics
Frequently Asked Questions
What is GILD's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Gilead Sciences, Inc's ratio is about N/A — common for comparing leveraged companies in Biotechnology.
Is N/A high or low vs peers?
EV/EBITDA norms differ in Biotechnology; compare GILD with closest business-model peers.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →